Neuroblastoma Drugs Market Size

Neuroblastoma drugs Market size was over USD 241.96 Billion in 2023 and is expected to exceed USD 467.68 Billion by 2036, growing at over 5.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of neuroblastoma drugs is evaluated at USD 253.92 Billion. The growth of the market can be attributed to the increasing childhood cancer and rising incidence of neuroblastoma. As per the estimations, more than 700 children are diagnosed with neuroblastoma each year in the United States as of 2023. The growing awareness of people regarding the diagnosis and treatment of cancer is estimated to drive market growth. The increasing occurrence of gender-specific and age-specific incident cases is expected to boost industry growth in the coming years. The rising occurrence of neuroblastoma from gene mutations in families is also estimated to hike industry growth.

The increasing research and development in neuroblastoma treatment owing to the rising expenditure on cancer treatment is estimated to drive market growth. The rising birth rate across the world and increasing clinical trials to improve treatment procedures are estimated to propel the growth of the market. The U.S. birth rate from 2020 to 2021 was estimated to increase by 1% after a decrease of 3% from 2019 to 2020.  The market  growth is attributed to the rising availability of reimbursement in the healthcare sector for the treatment of neuroblastoma. The government initiatives to increase healthcare expenditure across the globe to reduce the spread of diseases are also estimated to rise the demand for the market during the forecast period.